CONCORD, N.H. (AP) — Two New Hampshire fathers who were barred from school district events for wearing pink wristbands marked “XX” to represent female chromosomes insisted at a federal court hearing Thursday that they didn't set out to harass or otherwise target a transgender soccer player who played on the team. But a judge hearing the case suggested the message the parents sent may matter more than their intentions. Kyle Fellers and Anthony Foote sued the Bow school district after being banned from school grounds for wearing the wristbands at their daughters' soccer game in September. The no-trespass orders have since expired, but a judge is deciding whether the plaintiffs should be allowed to wear the wristbands and carry signs at upcoming school events, including basketball games, swim meets and a music concert, while the case proceeds. Testifying at Thursday's hearing, both men said that they did not view the wristbands as a protest against Parker Tirrell, a transgender girl on the opposing team, but rather as a show of support for their daughters and their teammates. U.S. District Court Judge Steven McAuliffe questioned whether there is a meaningful distinction and whether their intentions matter. “Sometimes the message you think you’re sending might not be the message that is being sent,” he said. McAuliffe asked Foote whether it occurred to him that a transgender person might interpret the pink XX wristbands as an attempt to invalidate their existence. “If he’s a trans female, pink might be a color he likes,” Foote said. McAuliffe also noted that while both plaintiffs said they had no problem with transgender people outside the issue of sports, they repeatedly referred to the athlete in question as a boy. “You seem to go out of your way to suggest there’s no such thing as a trans girl,” McAuliffe said. Foote disagreed, saying it was “like learning a new language” to refer to transgender people. In a separate courtroom earlier Thursday, another judge held a hearing on a lawsuit brought by Parker Tirrell and another student challenging the state law that bans transgender athletes in grades 5 to 12 from teams that align with their gender identity. It requires schools to designate all teams as either girls, boys or coed, with eligibility determined based on students’ birth certificates “or other evidence.” That federal judge ruled earlier this year that the teens can try out for and play on girls school sports teams. The order only applies to those two individuals for now as they seek to overturn the Fairness in Women’s Sports Act on behalf of all transgender girl students in New Hampshire. Lawyers for the teens said in court Thursday they hoped the matter could go to trial and be resolved before the start of the next school year in September. They said the teens’ school districts and others in the state have asked for guidance regarding the statute. Lawyers for the state said they needed more time to prepare. Judge Talesha Saint-Marc suggested the timing of the trial was ambitious and asked that both sides talk further about scheduling. Gov. Chris Sununu, who signed the Fairness in Women’s Sports Act into law in July, has said it “ensures fairness and safety in women’s sports by maintaining integrity and competitive balance in athletic competitions.” About half of states have adopted similar measures. In the Bow case, school district officials have said they acted appropriately in sanctioning the parents for conduct they knew violated school policy at athletic events. They'll explain their evidence on Friday. On Thursday, the plaintiff's lawyer, Endel Kolde, accused the district of “breathtaking” overreach by asserting that the wristbands target transgender students in general, regardless of whether such students were present at the events. “This is viewpoint discrimination, and it’s very clear they’re proud of it,” Kolde said. Kolde initially conceded that a school district can limit speech “to some degree” to protect children from harassment, but he stopped short of agreeing with the judge’s claim that yelling “transgender students out” at a particular player would be subject to such regulation. “It might be,” he said. “I’m trying to get you to concede the obvious,” McAuliffe said. “It’s less than obvious to me,” Kolde said. Feller, the first witness in the case involving the wristbands, said he purchased them thinking his daughter and her teammates would wear them, but ended up wearing one himself after they declined. After being told to leave the game, he stood in the parking lot with a sign that said “Protect women’s sports for female athletes.” “I wanted to support women’s sports and I believed what was going on was a travesty,” he said.iClick Interactive Asia Group Limited Reports 2024 Half-Year Unaudited Financial ResultsSeveral times following New England’s to the Buffalo Bills, Patriots coach Jerod Mayo said he wanted to review the game film before making a final assessment of his team’s performance. He did, and on Monday he said the overarching feeling he was left with was one of pride. Going toe-to-toe with one of the best teams in the NFL is commendable. Mayo also remains confident this group has even more room for growth over its final two games this season. “To be frank, I don’t believe in good losses,” Mayo said. “I think there’s a lot to learn from the game. Look, we’re headed in the right direction, but it’s all about consistency, and we have to do that on a down-after-down, a game-after-game basis to be successful in this league.” What is also clear is that despite their 3-12 record, Patriots rookie quarterback Drake Maye wants people to know that he and his teammates believe in their coach. No matter what conversations might be going on outside the Patriots locker room regarding shortcomings by the coaching staff, or Mayo’s job status. “We’ve got his back, and he’s coached us hard. He wants to win. We all want to win. We’re all frustrated,” Maye said. “We’re just plays away, and it’s basically me turning the ball over. I think it’s just a testament to these guys that keep fighting. We keep fighting. Shoot, we’re not going to make the playoffs; we’re out of the race, and these guys are coming in, frustrated when we don’t score. ... So, I think we’re building something good, building something that feels right here, and I’m proud to be a Patriot.” The Patriots entered the week scoring only 7.5 points per game in the first half this season, which ranked 29th in the NFL. The offense woke up with 14 points in the first half on Sunday, notching multiple offensive touchdowns in the first half for the first time in 2024. Stopping the run has been an issue for New England’s defense for most of the season and it was on display against the Bills. With Buffalo trailing 14-0 in the second quarter, running back James Cook sliced through the interior of the Patriots defense and broke free for a 46-yard TD run. It was a big chunk of Buffalo’s 172 yards on the ground for the game. CB Jonathan Jones. He was tasked with being the primary defender on Buffalo’s top receiver Khalil Shakir for most of the game. The veteran held his own, helping limit the Bills’ leader in catches and receiving yards to only two catches for 22 yards on six targets. Jones also forced a fumble by Shakir in the fourth quarter, though Shakir was able to recover it. Marte Mapu. The linebacker started at safety with Jabrill Peppers sidelined with a hamstring injury. Mapu was strong for most of the game and had a chance to set up the Patriots offense in the second quarter when he snagged his second career interception, picking off Josh Allen’s pass in the end zone. But Mapu decided to run the ball out of the end zone and was tackled on the New England 1-yard line. The poor starting field position eventually led to a punt and the Patriots couldn’t add to their 14-7 lead. The Patriots didn’t announce any injuries during the game. But along with Peppers, cornerback Marcus Jones also sat out with a hip injury. 2-6 — The Patriots’ record in one-score games this season. Four of those have been by three or fewer points. The Patriots host the Los Angeles Chargers on Saturday. AP NFL:mnl168 website 。

Airbags, advanced driver assistance features, and high-strength materials mean that the safest cars today are far better at protecting people from injuries than ever before. Although most new cars compare well to their predecessors, some stand above the rest. The safest cars for 2025 offer excellent occupant protection and also do a good job of preventing accidents from happening in the first place. Based on testing data from the Insurance Institute for Highway Safety , or IIHS, and the National Highway Traffic Safety Administration , or NHTSA, these are some of the safest cars available today. Ranging from inexpensive compact cars and mainstream midsize sedans to stylish station wagons, posh luxury cars, and sporty coupes and convertibles, Edmunds shares a list that has something for just about everyone. For those who prefer a higher seating position and maybe some added practicality, Edmunds’ list of safest SUVs is for you. You may like: Buying a car? How to avoid getting scammed The stylish Mazda 3 has a lot to offer compact-car shoppers, including great looks, a composed driving experience, and reasonable fuel economy from its base 2.0-liter engine. It’s also one of the safest cars in its class, earning a perfect five stars in NHTSA crash testing and sterling crashworthiness and collision avoidance scores from the IIHS. Its standard features are forward collision warning, automatic emergency braking, and lane departure prevention. With mature styling, a premium interior, and an efficient hybrid powertrain option, the 2025 Honda Civic is a great option if safety is a concern since it aces almost all of the IIHS’ crash tests and earns a five-star safety rating from the federal government. It also comes standard with adaptive cruise control, lane departure prevention, and forward collision warning with automatic emergency braking. The Civic falls short slightly in the IIHS’ updated moderate overlap front test, which now accounts for rear passenger safety, but even so, it’s one of the safest cars in its class. Reflective of parent company BMW, today’s Mini Cooper is well constructed and features premium safety features that belie its small size, including automatic emergency braking and forward collision warning. Although the Mini hasn’t been tested by NHTSA, the IIHS gives the Cooper its highest score of Good in the original driver-side small overlap front, moderate overlap front, and side-impact tests. That said, the IIHS doesn’t place the Cooper on its Top Safety Pick or Top Safety Pick+ lists since it hasn’t been evaluated on the updated battery of passenger-side small overlap front, moderate overlap front, or side-impact tests. Expect the new-for-2025 Mini Cooper to earn decent crash ratings in those scenarios, especially since it shares its strong platform with the outgoing model. With its recent redesign, the Toyota Prius transformed from a frumpy little caterpillar to a stylish and efficient butterfly. It also became a very safe hybrid hatchback. Perfect scores in all of its government and IIHS crash tests, as well as a sophisticated system of collision avoidance technology, earn it top marks. It’s also one of our favorite cars on the market, period, as evidenced by its status as a 2024 Edmunds Top Rated vehicle. The Honda Accord is among the safest midsize sedans on the market today thanks to excellent crashworthiness scores and a competent standard collision prevention system. It’s a Top Safety Pick+, beating out rivals like the Hyundai Sonata, Kia K5, and Subaru Legacy, and the Accord also earns a perfect five-star rating from NHTSA. Honda’s hybrid-intensive product planning is on full display here—all but the two lowest Accord trims have a hybrid powertrain—and it’s also among the most spacious cars in its class. Like its Honda Accord rival, the Toyota Camry is also an IIHS Top Safety Pick+ with a five-star NHTSA rating. It also has a very impressive suite of driver assistance and safety technology, including lane departure prevention with active centering, full-speed adaptive cruise control, and automatic emergency braking. The Camry edges out the Accord in IIHS testing thanks to a more effective collision avoidance system, but both cars are remarkably well matched otherwise. The fully electric Hyundai Ioniq 6 offers excellent safety and collision prevention, with excellent scores across the entire line of IIHS tests. The Ioniq 6 hasn’t been tested for rollover resistance by NHTSA, but it earned a four-star front safety rating and a five-star side-impact rating in government tests. Like most EVs, the Hyundai Ioniq 6 comes standard with forward collision warning, automatic emergency braking, and lane departure prevention. It also offers up to 342 miles of all-electric driving in its longest-range trim level. The Acura Integra is a close mechanical cousin to the Honda Civic, so it’s no surprise it does well in both the IIHS’ and NHTSA’s crash tests. The luxury hatchback is a Top Safety Pick+ and earns a perfect five stars in government testing. The AcuraWatch safety suite is standard on the Integra, bringing automatic emergency braking, lane centering, lane departure prevention, and adaptive cruise control. The Mercedes-Benz C-Class is a safe option in the popular small luxury sedan segment thanks to its good scores in IIHS crash testing. Mercedes’ best-selling sedan also comes standard with automatic emergency braking and forward collision warning, which helps it earn a Top Safety Pick award. However, it hasn’t been tested by the NHTSA. Both the Genesis G80 and the fully electric Genesis Electrified G80 earn a Top Safety Pick+ score from the IIHS thanks to their good scores on the agency’s crash tests, as well as a comprehensive suite of active safety features that avoided collisions with simulated pedestrians. The internal-combustion-engine G80 earned a perfect five-star safety rating from NHTSA, and although the Electrified G80 hasn’t been tested by the feds just yet, it should likely excel in those tests too. The flagship Genesis G90 sedan competes with the Mercedes-Benz S-Class and BMW 7 Series, and the South Korean automaker clearly hasn’t skimped on safety in its fight against the establishment. Although it hasn’t been subjected to the NHTSA array of tests, it aced almost all of its IIHS tests, and a long list of standard active safety and driver assistance features sets it apart from the stingy German makes that charge extra for them. With handsome styling and a well-finished interior, the Volvo V60 is a very appealing station wagon for those looking for such a thing. It’s also quite safe, with good crashworthiness scores in the IIHS’ original moderate overlap front and side-impact scores. Unfortunately, since it hasn’t been tested with the updated versions of those tests, it didn’t earn this year’s Top Safety Pick award, but it was called a Top Safety Pick+ in 2022. NHTSA also gives the V60 a five-star safety rating. Although the Mercedes-Benz E 450 All-Terrain isn’t a traditional wagon — it follows the lifted almost-crossover formula shared with the Audi A6 Allroad and Volvo V90 Cross Country — we’ll take what we can get in this dwindling category. The All-Terrain hasn’t been tested by the IIHS or NHTSA, but a previous-generation E-Class earned a 2023 Top Safety Pick+ award, and Mercedes isn’t the kind of company that goes backward when it comes to safety. The E 450 All-Terrain comes standard with automatic emergency braking and forward collision warning, though, at this price, Benz should just make other active safety features standard. With a five-star NHTSA safety rating, standard forward collision warning and emergency braking, and excellent IIHS crashworthiness scores on its original tests, the Audi A6 Allroad does a good job protecting people (both passengers and pedestrians) from crashes. However, since the IIHS hasn’t subjected the Allroad to its updated side and moderate front crash criteria, it lost its Top Safety Pick+ status in 2022. Still, it should be a fine option for luxury longroof shoppers. Both the Ford Mustang coupe and convertible perform well in crash testing. The coupe received a five-star safety rating from NHTSA, and both variants scored decently on all the IIHS tests they’ve undergone. They also come standard with forward collision warning, lane departure prevention, and automatic emergency braking. However, the IIHS needs to test both models on its updated criteria before it will rate them. Although the government hasn’t tested it, the Toyota GR86 aced all of its IIHS crashworthiness tests when it was new for the 2022 model year. Unfortunately, since it hasn’t been subjected to the IIHS’ updated testing since then, it lost its Top Safety Pick+ status. Still, this is a fun-to-drive, sporty coupe that comes standard with a long list of active safety features, and it’s reasonably priced to boot. Mechanically identical to the Toyota GR86, the 2025 Subaru BRZ achieves the same safety ratings—who would have thought? It likewise received a Top Safety Pick+ score in 2022 that lapsed when the IIHS updated its criteria for 2023, but like the Toyota, it has a long list of active safety features to go along with its lightweight, rip-roaring sports car attitude. The Audi A5 lost its traditional two-door coupe body style after 2024, but the five-door Sportback body style remains before it’s replaced later in 2025. Although it hasn’t seen the IIHS’ more stringent test regimen, its original crashworthiness scores were good enough to earn it a Top Safety Pick award as recently as 2022. The Sportback is the only variant to be tested by the government, where it earned a five-star safety rating. This story was produced by Edmunds and reviewed and distributed by Stacker. Want stories like this delivered straight to your inbox?Stay informed. Stay ahead. Subscribe to InqMORNING

KENSINGTON, P.E.I. — A feud over proposed pickleball courts in Prince Edward Island has prompted a longtime mayor to throw in the towel. Rowan Caseley says there was lots he still wanted to accomplish as mayor of Kensington, P.E.I., but he felt he had to resign Monday after the town council voted to build six pickleball courts Caseley says the community can't afford. He was mayor for about 10 years and a councillor for five years before that. "As mayor, one of the things I'm required to do is defend the decision of council, and I couldn't," Caseley said in an interview Wednesday. "It just went totally against my principles." He said his opposition is not meant as a critique of the local pickleball community, about a dozen of whom filled council chambers as the vote took place. The growing town simply has more pressing needs to tend to. Pickleball is much like tennis, but players hit a hollow perforated plastic ball, rather than a rubber tennis ball. The balls make a resonant popping sound when players hit them with their rackets, and the noise from pickleball courts has irritated neighbours and drawn complaints across the country. There are already several pickleball courts in Kensington, which is home to about 2,300 people, Caseley said. But at the urging of some councillors, the town put together a proposal for six new courts, a bathroom and a gravel parking lot, and submitted it to the 2023 Canada Games Legacy Fund, established after the province hosted the Games. When the fund said it would cover just 55 per cent of the $500,000 price tag, Caseley said he and senior staff members recommended that council abandon the project. But on Monday, Coun. Ivan Gallant put forward a motion to proceed with a scaled-down version of the project that would leave the town on the hook for roughly $20,000, said Geoff Baker, Kensington's chief administrative officer. The motion passed 3-2. Caseley said he interpreted it as a vote of non-confidence. Gallant is a member of the local pickleball community, though he denied urging fellow players to fill the chamber for the vote. "Anybody in our community is eligible to come to our meetings, they're open to the public," Gallant said in an interview. Caseley argued that even the scaled-down plan with the smaller price tag would still eat up staff time and operating costs. That time and money would be much better spent on projects to support the community's growing population, such as expanding its waste treatment system, the ex-mayor said. "Staff are going to have to drop other things that were a higher priority to deal with this," he said. "It's not in the best interest of the residents, the taxpayers or the town of Kensington. It's a want and not a need." Caseley said he wasn't yet sure what he would do with his new-found free time, but he has no interest in taking up pickleball. "I'm 77 years old, so I'm probably just going to sit back and read books," he said. This report by The Canadian Press was first published Nov. 27, 2024. Sarah Smellie, The Canadian PressNo. 7 Alabama looks to remain in playoff contention with a visit to Oklahoma

Suspect pleads not guilty in NYCLongtime P.E.I. mayor resigns after a contentious vote for pickleball courts

Stock market today: Losses for Big Tech pull US indexes lower

Why your favorite catalogs are smaller this holiday season

WARRINGTON, Pa., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or “the Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions, today reported financial results for the third quarter ended September 30, 2024 and provided key business updates. “The third quarter of 2024 was marked with significant progress. We were very pleased with the SEISMiC B study results in early cardiogenic shock showing significant improvement in many measures of cardiac function and blood pressure along with a favorable safety profile in patients with heart failure and cardiogenic shock. There have been four positive Phase 2 studies with over 300 patients treated with istaroxime resulting in a consistent, unique and attractive drug profile across a wide range of severities,” said Craig Fraser, Chairman and CEO. “With trial execution and active operations comes the need for capital and we successfully completed transactions providing resources for our near-term needs as well as secured an equity line of credit to potentially support future requirements,” Mr. Fraser added. “Looking forward, we plan to accelerate enrollments in the istaroxime SCAI Stage C cardiogenic shock study with a planned interim data read out in early Q2 2025 as well as providing guidance on our strategy and planned activities with our oncology preclinical aPKCi inhibitor assets. Given what we believe to be strong data and market need, the Company is turning attention to business development activities to secure additional licenses and partnerships for our multi-asset cardiovascular platform with the objective to secure non-dilutive capital and partner resources to advance the assets to potential commercialization.” Key Business Updates Announced positive Phase 2b topline clinical results with istaroxime significantly improving cardiac function and blood pressure in heart failure patients with early cardiogenic shock. The study met its primary endpoint in significantly improving systolic blood pressure over six hours (SBP AUC) for the combined Part A and Part B SEISMiC istaroxime group compared to placebo as well as for SEISMiC Part B alone. The improvements in SBP AUC at 24 hours were also significantly increased by istaroxime and the improvements were sustained through 96 hours of measurement. Cardiac output (the amount of blood pumped by the heart over a minute) and filling pressures in the heart significantly improved as did measured kidney function. Heart failure severity as assessed by the NYHA classification decreased significantly up to 72 hours compared to placebo. A favorable safety and tolerability profile, including risk for cardiac arrythmias, was also observed. The clinical study data was presented in a late-breaker session at the Heart Failure Society of America conference and the Company reviewed the clinical results along with the program strategy and plans at a virtual Investor Meeting which has been posted to the Company website. Completed two private placements in July 2024 for aggregate proceeds of approximately $13.9 million, which consisted of approximately $4.4 million of new funding (with $2.3 million of net proceeds) and a $9.5 million payment through the full cancellation and extinguishment of certain holders outstanding senior notes, including secured notes, and shares of the Company’s Series B Convertible Preferred Stock. Entered into a Common Stock Purchase Agreement with an equity line investor, whereby the Company has the right, but not the obligation, to sell such investor, and, subject to limited exceptions, the investor is obligated to purchase for up to $35 million of newly issued shares of the Company’s common stock. Announced initiation of the SEISMiC C study of istaroxime in SCAI Stage C cardiogenic shock to complete Phase 2b and advance the transition to Phase 3. This is a global trial including sites in the U.S., Europe and Latin America. It is a placebo-controlled, double-blinded study with istaroxime being added to current standard of care with inotropes and/or vasopressors. The effect of istaroxime in addition to these therapies will be assessed for 6 hours and based on the patient’s condition, the ability to remove standard of care therapies while on istaroxime will also be assessed. The primary endpoint of the study is assessment of systolic blood pressure (SBP) profile over the first 6 hours of treatment. Expanded patent estate with new patents with istaroxime in cardiogenic shock and acute heart failure. Cardiogenic shock national phase filings were completed for patent applications around the world, including in the United States, Germany, France, Italy, Japan and China. A patent was issued for istaroxime for Japan entitled, “Istaroxime-containing intravenous formulation for the treatment of heart failure and it has been accorded Patent No. 7560134. A patent was issued for istaroxime for Hong Kong, and it is entitled, “Istaroxime-containing intravenous formulation for the treatment of heart failure (AHF).” The claims are directed formulations comprising istaroxime, pharmaceutically acceptable salts thereof, and methods of use, alone, or in combination with other agents useful for the treatment and management of acute heart failure. Select Third Quarter 2024 Financial Results For the third quarter ended September 30, 2024, the Company reported an operating loss of $4.7 million, which was comparable to an operating loss of $4.7 million in the third quarter of 2023. Included in our operating loss for the third quarter of 2024 is $2.2 million related to the change in fair value of our common stock warrant liability and $0.7 million in expenses related to the two private placements completed in July 2024 which were allocated to the warrants issued in those transactions and expensed immediately. Research and development expenses were $2.0 million for the third quarter of 2024, compared to $2.1 million for the third quarter of 2023. Research and development expenses for both periods primarily relate to the SEISMiC Extension trial of istaroxime for the treatment of early cardiogenic shock which completed enrollment during the third quarter of 2024. General and administrative expenses for the third quarter of 2024 were $2.8 million, compared to $2.6 million for the third quarter of 2023. For the third quarter of 2024, general and administrative expenses include $0.7 million in expenses related to the two private placements completed in July 2024 which were allocated to the warrants issued in those transactions and expensed immediately. The Company reported a net loss attributable to common stockholders of $3.8 million ($4.23 per basic share) on 0.9 million weighted-average common shares outstanding for the quarter ended September 30, 2024, compared to a net loss of $4.4 million ($15.47 per basic share) on 0.3 million weighted average common shares outstanding for the comparable period in 2023. As of September 30, 2024, the Company reported cash and cash equivalents of $2.3 million and current liabilities of $14.4 million, which includes an $8.6 million warrant liability. Included in prepaid expenses and other assets as of September 30, 2024 is $0.7 million in receivables related to ELOC Purchase Agreement gross proceeds for sales made during the quarter for which we had not yet received the cash payment. The related net proceeds after the redemption of the Series C Preferred Stock was $0.5 million. In addition, subsequent to September 30, 2024 and through November 22, 2024, we sold an additional 4.3 million shares of Common Stock under the ELOC Purchase Agreement for net proceeds of $2.4 million following mandatory redemption payments on our Series C Preferred Stock. Following these financings, we believe that we have sufficient resources available to fund our business operations through January 2025. Readers are referred to, and encouraged to read in its entirety, the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2024, which was filed with the Securities and Exchange Commission on November 26, 2024, and includes detailed discussions about the Company’s business plans and operations, financial condition, and results of operations. Nasdaq Update On November 21, 2024, the Company received a letter from the Nasdaq Listing Qualifications Staff (“Staff”) of The Nasdaq Stock Market LLC stating that it was not in compliance with Nasdaq Listing Rule 5250(c)(1) as a result of it not having timely filed its Quarterly Report on Form 10-Q (“Form 10-Q”) for the quarter ended September 30, 2024 with the Securities and Exchange Commission. Based on the November 26, 2024 filing of the Company’s Form 10-Q and a subsequent letter received from Nasdaq on November 27, 2024 stating the Staff has determined that the Company complies with Nasdaq Listing Rule 5250(c)(1), this matter is now closed. About Windtree Therapeutics, Inc. Windtree Therapeutics, Inc. is a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases. Windtree’s portfolio of product candidates includes istaroxime, a Phase 2 candidate with SERCA2a activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure and preclinical precision aPKCi inhibitors that are being developed for potential in rare and broad oncology applications. Windtree also has a licensing business model with partnership out-licenses currently in place. Forward Looking Statements This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The Company may, in some cases, use terms such as "predicts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are based on information available to the Company as of the date of this press release and are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from the Company’s current expectations. Examples of such risks and uncertainties include, among other things: the Company’s ability to secure significant additional capital as and when needed; the Company’s ability to achieve the intended benefits of the aPKCi asset acquisition with Varian Biopharmaceuticals, Inc.; the Company's risks and uncertainties associated with the success and advancement of the clinical development programs for istaroxime and the Company’s other product candidates, including preclinical oncology candidates; the Company’s ability to access the debt or equity markets; the Company’s ability to manage costs and execute on its operational and budget plans; the results, cost and timing of the Company’s clinical development programs, including any delays to such clinical trials relating to enrollment or site initiation; risks related to technology transfers to contract manufacturers and manufacturing development activities; delays encountered by the Company, contract manufacturers or suppliers in manufacturing drug products, drug substances, and other materials on a timely basis and in sufficient amounts; risks relating to rigorous regulatory requirements, including that: (i) the U.S. Food and Drug Administration or other regulatory authorities may not agree with the Company on matters raised during regulatory reviews, may require significant additional activities, or may not accept or may withhold or delay consideration of applications, or may not approve or may limit approval of the Company’s product candidates, and (ii) changes in the national or international political and regulatory environment may make it more difficult to gain regulatory approvals and risks related to the Company’s efforts to maintain and protect the patents and licenses related to its product candidates; risks that the Company may never realize the value of its intangible assets and have to incur future impairment charges; risks related to the size and growth potential of the markets for the Company’s product candidates, and the Company’s ability to service those markets; the Company’s ability to develop sales and marketing capabilities, whether alone or with potential future collaborators; the rate and degree of market acceptance of the Company’s product candidates, if approved; the Company’s ability to maintain compliance with the continued listing requirements of Nasdaq; the economic and social consequences of the COVID-19 pandemic and the impacts of political unrest, including as a result of geopolitical tension, including the conflict between Russia and Ukraine, the People’s Republic of China and the Republic of China (Taiwan), and the evolving events in the Middle East, and any sanctions, export controls or other restrictive actions that may be imposed by the United States and/or other countries which could have an adverse impact on the Company’s operations, including through disruption in supply chain or access to potential international clinical trial sites, and through disruption, instability and volatility in the global markets, which could have an adverse impact on the Company’s ability to access the capital markets. These and other risks are described in the Company’s periodic reports, including its Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, filed with or furnished to the Securities and Exchange Commission and available at www.sec.gov. Any forward-looking statements that the Company makes in this press release speak only as of the date of this press release. The Company assumes no obligation to update forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release. Contact Information: Eric Curtis ecurtis@windtreetx.comBiden commutes 37 of 40 death row sentences

Awfis Space Solutions shares will remain in focus on Wednesday as promoter Peak XV Partners Investments and shareholders Bisque Ltd and Link Investment Trust plan to sell a 12.2% stake in the company through a block deal, CNBC-TV18 reported. The stake sale , valued at Rs 583.4 crore, is priced at Rs 680 per share, a 5.2% discount to the last closing price on the National Stock Exchange (NSE). Sources said the deal includes a 90-day lock-in period. Peak XV owns a 22.86% stake in Awfis, Bisque holds 23.47%, and Link Investment Trust has 0.36%. Awfis offers flexible workspace solutions, from individual desks to customized office spaces for corporates. Also Read : DLF Camellias' Rs 190 crore Gurugram apartment: How many Bitcoins would you need? In November, Awfis announced a partnership with the National Stock Exchange (NSE) to design, build, and manage over 1.65 lakh square feet of office space at Adani Inspire in Mumbai's Bandra-Kurla Complex (BKC). Stock Trading Markets 102: Mastering Sentiment Indicators for Swing and Positional Trading By - Rohit Srivastava, Founder- Indiacharts.com View Program Stock Trading ROC Made Easy: Master Course for ROC Stock Indicator By - Souradeep Dey, Equity and Commodity Trader, Trainer View Program Stock Trading Market 103: Mastering Trends with RMI and Techno-Funda Insights By - Rohit Srivastava, Founder- Indiacharts.com View Program Stock Trading Derivative Analytics Made Easy By - Vivek Bajaj, Co Founder- Stockedge and Elearnmarkets View Program Stock Trading Options Trading Course For Beginners By - Chetan Panchamia, Options Trader View Program Stock Trading A2Z of Stock Market for Beginners: Stock Market Course For Beginners By - elearnmarkets, Financial Education by StockEdge View Program Stock Trading Technical Analysis Made Easy: Online Certification Course By - Souradeep Dey, Equity and Commodity Trader, Trainer View Program Stock Trading A2Z of Stock Trading - Online Stock Trading Course By - elearnmarkets, Financial Education by StockEdge View Program Stock Trading Stock Markets Made Easy By - elearnmarkets, Financial Education by StockEdge View Program Stock Trading Ichimoku Trading Unlocked: Expert Analysis and Strategy By - Dinesh Nagpal, Full Time Trader, Ichimoku & Trading Psychology Expert View Program Stock Trading Futures Trading Made Easy: Future & Options Trading Course By - Anirudh Saraf, Founder- Saraf A & Associates, Chartered Accountant View Program Stock Trading Market 101: An Insight into Trendlines and Momentum By - Rohit Srivastava, Founder- Indiacharts.com View Program Stock Trading Dow Theory Made Easy By - Vishal Mehta, Independent Systematic Trader View Program This agreement covers two floors in one of the city's prime commercial hubs. The BKC area is connected to the Aqua Line of the metro and the Bandra suburban station and is a preferred business destination in Mumbai, the company said. With the addition of this new mandate, the company expands its footprint in the building, where it already operates a coworking centre, Awfis said. The deal was facilitated by Rounak Real Estate Consultants, an advisory firm with expertise across prime residential, commercial, and industrial spaces. Also Read : Vishal Mega Mart IPO opens today. Check GMP, review On Tuesday, Awfis Space shares closed at Rs 716.9, down 0.15% on the BSE, while the benchmark Sensex ended flat. The stock has gained 62% in the past six months, bringing the company’s market capitalization to Rs 5,078 crore. ( Disclaimer : Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of The Economic Times) (You can now subscribe to our ETMarkets WhatsApp channel )in Beverly Hills after sharing dinner with , wife of Kansas City Chiefs tight end Blake Bell. , which occurred in January, where the pop star is seen being gracious to the kitchen staff. Although in a hurry, Swift politely said goodbye before disappearing into the night. The clip generated a wave of reactions on social media, especially among From strategic umbrellas to theories about hiding in a suitcase, , making it clear that even in casual situations, they are a true force of style. The escape through the kitchen, accompanied by the escort of three men, not only highlights the level of attention Swift and her friends generate, but also her constant kindness to the behind-the-scenes staff. "Thank you so much," the star was heard saying, a gesture that did not go unnoticed by fans. This difficult situation confirms once again that neither she nor Travis Kelce are made of steel; they are real, vulnerable, flesh-and-blood human beings. What is going on with Taylor Swift? , as she prepares for the emotional finale of her record-breaking Eras Tour. With just three dates remaining, the 34-year-old superstar is set to wrap up her epic two-year, 149-show tour on December 8 in Vancouver, Canada. According to close sources, the pop icon has been "super excited" to say goodbye to a tour that not only defined her professional life, but also bonded her deeply with her team, whom she considers her second family. However, The conclusion of the Eras Tour coincides with the intense NFL season, where Travis Kelce and the Kansas City Chiefs are seeking a historic third consecutive title to cement their dynasty. This titanic mission could divert player attention at a particularly vulnerable time for Taylor, who faces the emotional challenge of closing a monumental chapter in his career. A style move or a strategy to preserve her privacy? Whatever the case, , even in the least expected place: the back of a kitchen. Meanwhile, fans are wondering if she and Travis Kelce will be able to balance the pressure of their worlds while supporting each other in this emotionally challenging time. Only time will tell, but